Maze Therapeutics’ (MAZE) Outperform Rating Reaffirmed at Wedbush

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “outperform” rating reissued by Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $48.00 target price on the stock. Wedbush’s price objective points to a potential upside of 69.13% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. Finally, Citigroup assumed coverage on Maze Therapeutics in a report on Wednesday. They issued a “buy” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $64.89.

Maze Therapeutics Stock Up 26.8%

Maze Therapeutics stock opened at $28.38 on Wednesday. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The stock’s fifty day simple moving average is $27.21 and its 200-day simple moving average is $29.30. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.58 billion, a P/E ratio of -11.26 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, equities analysts expect that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. This trade represents a 65.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 191,459 shares of company stock valued at $5,263,539. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC lifted its holdings in shares of Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after purchasing an additional 5,822 shares during the period. Frazier Life Sciences Management L.P. grew its position in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after buying an additional 465,641 shares during the last quarter. AXQ Capital LP increased its stake in Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after buying an additional 8,098 shares during the period. Braidwell LP purchased a new position in Maze Therapeutics during the 2nd quarter worth $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Maze Therapeutics by 4,054.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after acquiring an additional 17,312 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.